68 citations
,
May 2012 in “Annals of Oncology” Some breast cancer chemotherapy can cause permanent hair loss.
1 citations
,
December 2012 in “Journal of dermatological science” Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
4 citations
,
January 1987 in “Beiträge zur Onkologie/Contributions to oncology” Adriamycin and ifosfamide together work best for advanced soft tissue sarcomas.
February 1961 in “The Lancet” Some new drugs show potential for treating blood cancers but have serious side effects and need more research.
39 citations
,
January 2015 in “Cochrane library” Chemotherapy may help with survival in children with medulloblastoma, but more research is needed.
3 citations
,
February 2005 in “Lung Cancer” The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.
12 citations
,
January 2016 in “Journal of clinical biochemistry and nutrition” Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.
14 citations
,
October 2003 in “Annals of Oncology” About half the patients treated with capecitabine and docetaxel developed severe hand-foot syndrome.
September 2012 in “International Current Pharmaceutical Journal” CHOP chemotherapy causes many side effects but is generally well tolerated.
February 2025 in “Chemico-Biological Interactions” 5-Fluorouracil causes hair loss by blocking signals needed for hair growth.
1 citations
,
April 2024 in “Anais Brasileiros de Dermatologia” 22 citations
,
May 2011 in “European Journal of Cancer” The drug combination was safe and showed promise in treating advanced tumors.
1 citations
,
February 2023 in “Daehan ui'sa hyeobhoeji/Daehan uisa hyeopoeji” Primary healthcare clinics are key in managing chemotherapy side effects using various medications and treatments.
More research is needed to understand chemotherapy-induced hair loss and its phases.
279 citations
,
June 1990 in “Journal of Clinical Oncology” Adding chemotherapy to tamoxifen improves survival for older breast cancer patients with positive nodes.
January 2021 in “Annals of translational medicine” YH0618 helped reduce skin and nail problems and fatigue in chemotherapy patients.
November 2025 in “Preprints.org” Phenytoin and spironolactone help prevent hair loss from chemotherapy by reducing stress and inflammation.
21 citations
,
September 2015 in “International journal of gynaecology and obstetrics” Chemotherapy is crucial for treating gynecological cancers but requires careful management due to severe side effects.
September 2013 in “Oncology Times” Oncology specialists are disappointed by the discontinuation of the effective lymphoma treatment Bexxar.
3 citations
,
September 2016 in “Dermatologic Therapy” Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.
November 2021 in “World Family Medicine Journal /Middle East Journal of Family Medicine” COVID-19 affects patients on chemotherapy for gynecological cancer negatively.
1 citations
,
October 2019 in “Journal of Thoracic Oncology” Chemotherapy adds to, but doesn't enhance, the effects of immunotherapy in lung cancer treatment.
39 citations
,
August 2022 in “Pharmaceutics” Combining letrozole and quercetin in spanlastics may improve breast cancer treatment.
522 citations
,
January 2001 in “Cancer investigation” Doxil is an effective, modified chemotherapy drug with a unique toxicity profile and shows promise in treating certain cancers.
5 citations
,
February 2016 in “International Journal of Cancer” Topical vasoconstrictors do not reduce chemotherapy effectiveness against leukemia in mice.
93 citations
,
May 2010 in “European Journal of Cancer” BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.
June 2021 in “Research Square (Research Square)” Adverse events in lung cancer treatments increase fear, anxiety, and depression, with newer therapies causing fewer side effects.
1 citations
,
January 2022 in “Journal of Cancer Therapy” Ocoxin improves quality of life for advanced ovarian cancer patients on chemotherapy.
46 citations
,
December 1997 in “Cancer Nursing” CHOP chemotherapy for non-Hodgkin's lymphoma commonly causes hair loss, fatigue, taste changes, and nausea.
6 citations
,
May 2013 in “Journal of Clinical Oncology” Combining Ficlatuzumab and Gefitinib can cause severe hair loss.